Oragenics (NYSE:OGEN) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research report released on Wednesday morning. The brokerage issued a sell rating on the stock.

Oragenics Trading Down 19.3 %

NYSE OGEN opened at $1.80 on Wednesday. The business’s 50-day moving average is $1.25. The firm has a market cap of $8.07 million, a PE ratio of -0.21 and a beta of 0.50. Oragenics has a 52-week low of $0.86 and a 52-week high of $7.74.

Oragenics (NYSE:OGEN) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC bought a new position in shares of Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics as of its most recent filing with the SEC. 18.71% of the stock is owned by hedge funds and other institutional investors.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.